# Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

> **NCT00959439** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 34 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Osteoarthritis

## Interventions

- **DRUG:** Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
- **DRUG:** Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)

## Key facts

- **NCT ID:** NCT00959439
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2002-05
- **Final completion:** 2002-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00959439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00959439, "Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00959439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*